Conference abstractPublished 30 Jan 2017
Randomized controlled clinical trial open to 24 weeks of efficiency and safety in outpatient with obesity grade I and II treated with Clobenzorex vs. Clobenzorex with melatonin
Instituto Politecnico Nacional, Mexico
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Obesity is a disease characterized by the excess of adipose tissue (fat) in the body. Such disease is determined in adult persons when there is a Body Mass Index (BMI) is equal or higher than 30 kg/m2. Purpose: To evaluate the efficacy and safety of Clobenzorex 60 mg/Melatonin 3 mg (morning or night) against to Clobenzorex 60 mg in Mexicans with exogenous obesity during 24 weeks. Methodology: It was a longitudinal, prospective and comparative study. This study was conducted under 180 exogenous obese patients, administered: (1) Treatment âÂ?Â?AâÂ? (Clobenzorex 60 mg/Melatonin 3 mg 1 capsule VO, morning), (2) Treatment âÂ?Â?BâÂ? (Clobenzorex 60 mg/capsule VO Melatonin 3 mg one night) or (3) Treatment âÂ?Â?CâÂ? (60 mg 1 capsule Clobenzorex VO, morning). Efficacy was evaluated by weight loss (kg), BMI, waist-to-hip ratio (WHR) and percentage of body fat. On the other hand safety was evaluated by recording adverse events occurred. Results: The treatment âÂ?Â?AâÂ? causes polydipsia, xerostomia and headache, treatment âÂ?Â?BâÂ? had a safety advantage for shorter duration and number of adverse events. Finally, âÂ?Â?CâÂ? treatment compared to âÂ?Â?AâÂ? and âÂ?Â?BâÂ?âÂ? treatment, had the lowest rate of adverse effects by causing only one, which could be polydipsia, headache or constipation. Conclusion & Significance: All treatments were clinically effective. Greater reduction of the WHR and waist circumference was observed when using Clobenzorex. However, Clobenzorex/Melatonin (night) resulted safer due to the lower number and duration of adverse events.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Pamela Georgina Avila Lamadrid”
- BylineArticles whose byline prints “Magdaleno Rodriguez Daniel Roberto”
- BylineArticles whose byline prints “Sanchez Flores Jessica”
- BylineArticles whose byline prints “Cortes Moreno Gabriela Yanet”
- BylineArticles whose byline prints “Lara Padilla Eleazar”